By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

Key Statistics

Email: n/a
Ownership: Public

Web Site: AmpliPhi Bio
Symbol: APHB


Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.

Company News
AmpliPhi Bio (APHB) Announces Presentation Of Personalized Bacteriophage Therapy Case Study For Life-Threatening Antibiotic-Resistant Infection At Scientific Conference 4/25/2017 6:37:47 AM
AmpliPhi Bio (APHB) Announces Positive Feedback From FDA On Phase II Development Proposal 4/17/2017 10:18:55 AM
AmpliPhi Bio (APHB) Announces Planned One-for-Ten Reverse Stock Split 4/17/2017 9:15:42 AM
AmpliPhi Bio (APHB) Reports 2016 Fourth-Quarter And Full-Year Results And Provides Corporate Highlights 3/28/2017 7:21:10 AM
AmpliPhi Bio (APHB) Establishes Scientific Advisory Board And Appoints Dr. Timothy Lu Of MIT And Broad Institute As SAB Chairman 2/23/2017 6:26:26 AM
AmpliPhi Bio (APHB) Appoints Dr. Igor P. Bilinsky As Senior Vice President And Chief Operating Officer 1/30/2017 9:48:52 AM
Renowned Sinus Surgeon Dr. Peter-John Wormald Comments On AmpliPhi Bio (APHB)’ Favorable Phase I Results Of AB-SA01 In Chronic Rhinosinusitis Patients 1/4/2017 11:21:22 AM
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients 12/20/2016 10:33:35 AM
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients 12/19/2016 8:09:53 AM
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase I Trial Of AB-SA01 12/5/2016 11:24:52 AM